Multiomic Profiling Reveals Pleiotropic Effects of Somatic IRF4-C99R Mutations in Primary Mediastinal Large B-Cell Lymphomas

Introduction: Interferon Regulatory Factor 4 (IRF4) is a transcription factor that plays a critical role in the regulation of pre-B-cell development, the germinal center reaction as well as plasma cell differentiation. IRF4 has emerged as a master regulator of cancer-specific gene expression programs in various lymphoid malignancies. Prior studies uncovered a hotspot missense mutation in the DNA-binding domain of IRF4 (C99R) that alters the affinity of binding to specific DNA motifs and leads to disease-specific changes in classic Hodgkin lymphoma (Schleussner et al, 2023). The C99R mutations were also found to be recurrently detected in primary mediastinal large B-cell lymphoma (PMBCL) (Mottok et al, 2019, Noerenberg et al, 2023); however, its functional role in PMBCL pathogenesis remains unknown.

Materials and methods: We introduced the C99R mutation into two PMBCL-derived cell lines (U2940, Karpas-1106P) by applying CRISPR prime editing. We then performed ATAC-seq, ChIP-seq, and RNA-seq analyses on our isogenic model systems (IRF4^WT and IRF4^C99R). We also analyzed single cell (sc) transcriptome data of nuclei isolated from formalin-fixed paraffin-embedded tissues samples of primary PMBCL (n=4) with/without this mutation, including control tissues from reactive lymph node (n=2), and normal thymus (n=2).

Results: A meta-analysis of publicly available sequencing data revealed IRF4^C99R hotspot mutations in 29 out of 413 PMBCL samples (7%), compared to only 2 out of 1,999 diffuse large B-cell lymphoma samples (0.1%) (p<0.00001). To characterize the role of this mutation, we compared the global chromatin accessibility profiles between IRF4^WT and IRF4^C99R PMBCL cells by ATAC-seq and identified regions with commonly enhanced (1,334 regions) and reduced (2,796 regions) accessibility across the isogenic models. Specifically, in IRF4^C99R cells, the accessibility of flanking regions at specific EICE- and canonical/non-canonical AICE-motifs were elevated but clearly reduced at ISRE motifs. The direct IRF4 binding to these distinct motifs was validated by IRF4 ChIP-seq. In line with these results, differential gene expression analysis revealed down-regulation of key regulators of plasma cell differentiation such as PRDM1 and interferon gamma (IFNγ) signaling-related genes such as TNIK in IRF4^C99R cells, both genes were regulated by IRF4 at ISRE DNA motifs. Conversely, a key cytokine in PMBCL CCL17 (TARC) was upregulated at both the mRNA and protein levels in IRF4^C99R cells, as validated by qPCR and ELISA, respectively. Previous studies reported downregulation of TARC by IFNγ signaling, a finding that we reproduced by IFNγ stimulation experiments in our PMBCL models. Moreover, we showed that inhibition of TNIK abrogated IFNγ-mediated downregulation of TARC, demonstrating a mechanistic link between IRF4^C99R and increased TARC expression. Finally, we found the receptor tyrosine kinase encoding gene EPHB1, regulated at both EICE and AICE motifs, was the highest upregulated gene in IRF4^C99R cells (adj. p<0.01). Of note, the higher expression of both TARC and EPHB1 mRNA in primary PMBCL tumors carrying the IRF4^C99R (n=3) compared to IRF4^WT (n=63) were validated by Illumina Whole-Genome DASL assay.

We next performed in vitro binding assays and found EPHB1 specifically interacts with the membrane-bound ligand Ephrin-B2. Functional studies showed Ephrin B2-mediated adhesion and migration were significantly increased in IRF4^C99R cells. Moreover, we retrovirally engineered Eu-Myc mouse lymphoma cells to overexpress EPHB1 in an in-vivo syngeneic model. After intraperitoneal injection into C57BL6 mice, the cells with EPHB1 overexpression promoted enhanced tumor growth with increased infiltration of spleen, liver and thymus. Finally, sc transcriptome analysis showed significantly higher EPHB1 expression in primary PMBCL tumor cells with the IRF4^C99R mutation (n=2, p<0.001) as compared to cases with IRF4^WT (n=2), and the expression was rarely detected in normal B cells. Ephrin-B2 ligand expression was detectable in the endothelial cells of PMBCL tumors.

Conclusion: Our findings highlight pleiotropic effects of the heterozygous IRF4^C99R mutation leading to hallmarks of PMBCL lymphomagenesis including a plasmacytic differentiation block, upregulation of the key cytokine TARC, and providing a potential explanation of disease specific tropism through the Ephrin-B2/EPHB1 axis.

Fujisawa:Gilead Sciences, Inc: Research Funding. Savage:Regeneron: Other: DSMC; AbbVie: Consultancy; Bristol Myers Squibb: Consultancy, Research Funding; Seagen: Consultancy, Honoraria, Research Funding. Scott:Roche: Research Funding; Janssen: Consultancy; Incyte: Consultancy; AstraZenenca: Consultancy; Abbvie: Consultancy. Steidl:Trillium Therapeutics Inc: Research Funding; Bayer: Consultancy; EISAI: Consultancy; Bristol Myers Squibb: Research Funding; Seattle Genetics: Consultancy; AbbVie: Consultancy; Epizyme: Research Funding.